SLFN11 and hepatocellular carcinoma: Rather than a by‐effect of an IFN‐γ‐rich milieu, SLFN11 itself actively regulated the immune landscape and was associated with the efficacy of anti‐PD‐1 therapy in hepatocellular carcinoma [40].